Just need a reagent to share with the scientific community or interested in complete ownership for pursuing an exclusive proprietary application, Base Pair can provide the level of service you need.
Our revolutionary multiplexed aptamer technology allows us to offer very low aptamer discovery pricing. This pricing allows a low-risk, low-cost entry point into testing aptamers to your target and in your specific application. Instead of a large fixed aptamer discovery price up front, multiple checkpoints in a typical project (see below) allow you to minimize your risk before fully committing to commercialization with any given aptamer.
Even if you’ve tried aptamers unsuccessfully before, our business model and technical advances likely warrant you to look at aptamers again.
Target Submission and 50% payment Aptamer Selection (~4-6 weeks for most projects) In vitro binding validation (Kd determination, ~1-2 weeks) Second half payment and aptamer material (clonal DNA) delivery with modifications for downstream assays. This payment is only required if Base Pair can provide validated aptamers.
Using the validated, clonal materials discovered above, you will test the aptamer in the intended application. Any remaining material from validation can be included as part of your discovery pricing. Contact Us and let’s discuss your project.
III. Data Rights
If the aptamer is to be used for research use only no further payment is required and you can have continued access to the aptamer material though the catalogs along with other researchers, sequence transfer can be arranged for publication or other research use but aptamer intellectual property remains with Base Pair Biotechnologies.
Interested in exclusivity or commercializing your aptamer in a diagnostic assay or other application? For an additional fee Base Pair will transfer all intellectual property rights to any aptamers selected during a project. If the option for ownership is not desired any validated aptamers will be added to our Available Catalog Aptamers for research use or commercialization by others.